Comprehensive Guide to Pulmonary, Psychotropic, and Neurological Pharmacology

Pulmonary Medication Delivery Methods and Efficacy

Before discussing pharmacological agents, it is essential to understand the methods of administering drugs to pulmonary tissues. Systemic delivery involves drugs given orally or through subcutaneous or intramuscular injections. While these drugs eventually reach the pulmonary tissues via the pulmonary circulation, they are not selective for the respiratory tract and travel throughout the entire body. This method is advantageous when the airway is obstructed, such as during an acute asthma attack or severe chronic obstructive pulmonary disease (COPD). However, the primary drawback is the unintended distribution to non-target tissues. Conversely, inhalation is the preferred route for targeting the lungs directly. This method provides local effects, often requiring lower doses which results in fewer side effects at therapeutic levels. Primary delivery options include metered-dose inhalers (MDIs), nebulizers, and dry powder inhalers.

A metered-dose inhaler (MDI) is a highly portable and convenient device where the patient pushes down on a canister to inhale the drug. However, successful use requires significant coordination and timing; the patient must inhale deeply at the exact moment the canister is pressed. To mitigate these timing issues, spacers—plastic tubes placed between the mouth and the canister—can be used to hold the medication, allowing the patient more time to inhale. A nebulizer is a more extensive treatment that converts the drug into an aerosol form, typically inhaled over a period of $15$ to $20 \text{ minutes}$. An advantage of the nebulizer is that its smaller particles have a better chance of penetrating deep into the airway, which is particularly valuable when there is chronic or acute airway obstruction.

Respiratory Tract Irritation and Cough Medications

Respiratory tract irritation and excessive secretion often occur due to short-term issues such as seasonal allergies, the common cold, or influenza. Medications used to address these symptoms include antitussives, antihistamines, and decongestants. Antitussives, or cough medicines, are designed to suppress coughing. They include opioids like codeine and synthetic derivatives such as dextromethorphan and hydrocodone. These are frequently found in combination with other over-the-counter (OTC) products. While effective, there are concerns regarding dependence with opioid-based cough medicines. Furthermore, coughing is a protective mechanism meant to clear mucus and particles from the airway; limiting a productive cough extensively may be counterproductive unless the cough becomes so frequent that it irritates the airway.

There is significant concern regarding the efficacy of cough medications, particularly in children. The American College of Chest Physicians suggests that cough medications offer no symptomatic relief for acute coughing in children. Given that these medications contain active chemicals, the risk-benefit ratio is considered "upside down," as there is a risk of side effects with no physiological benefit. In young children, use is deemed inappropriate and can lead to adverse reactions. Alternative treatments, such as honey, are encouraged for pediatric cough control.

Antihistamines and Receptor Specificity

Antihistamines are commonly used to treat symptoms like coughing, sneezing, runny nose, and itchy eyes associated with colds or allergies. They specifically block the histamine type $1$ ($H_1$) receptor in the respiratory tract. This is distinct from the histamine type $2$ ($H_2$) receptors found in the stomach. Traditional antihistamines are effective but are known for being profoundly sedating, often causing a "foggy" feeling and decreasing cognition and reflex time. Newer agents, such as Clarinx and Allegra, categorized as non-sedating, were developed to avoid these effects by not crossing the blood-brain barrier easily.

While these newer agents are generally preferred because they do not impair reflex activity or coordination, some patients find them less effective than conventional, "old-school" antihistamines. The primary side effects of antihistamines that cross the blood-brain barrier include profound sedation, fatigue, lack of coordination, and blurred vision. Because of these risks, warnings against driving or operating machinery are standard on antihistamine packaging.

Decongestants, Mucolytics, and Expectorants

Decongestants are alpha-$1$ receptor agonists that stimulate these receptors on vascular arterioles, acting as vasoconstrictors. This action constricts the nasal mucosa to reduce the dilation associated with colds and allergies. Examples include pseudoephedrine and drugs that act similarly to epinephrine (adrenaline). While common in OTC sprays and combination products, these drugs can cause systemic effects if overused. Serious concerns include cardiac stimulation, such as palpitations and increased blood pressure. Monitoring heart rate and blood pressure is recommended for patients using these products, and clinicians should watch for adrenaline-like effects such as hand tremors or confusion, especially in patients with pre-existing hypertension.

Mucolytics and expectorants are used to facilitate airway clearance. Mucolytics, such as acetylcysteine (marketed as Mucomyst), work by breaking the disulfide bonds in mucus, making it less viscous and easier to expel. Interestingly, acetylcysteine also serves as an antidote for acetaminophen poisoning by neutralizing toxic metabolites in the liver. A more potent mucolytic, Dornase alpha (Pulmozyme), breaks up DNA released from dead cells in the airway, which otherwise makes mucus very sticky. This is particularly beneficial for patients with cystic fibrosis. Expectorants, such as guaifenesin (found in Mucinex), increase the fluid content of phlegm, making it thinner and easier to cough up. Overuse of these agents may cause nausea, vomiting, or mouth irritation, but they generally support clinical techniques like postural drainage and vibration.

Questions & Discussion: Clinical Scenario of Decongestants and Hypertension

A clinical scenario involves a patient with low back pain and well-managed hypertension (controlled by diuretics and ACE inhibitors) who begins taking an OTC cough and cold medication for an upper respiratory infection. The patient presents with a hand tremor and confusion. In such a case, the clinician should determine the exact ingredients of the OTC product. If the product contains alpha-$1$ agonists like pseudoephedrine, these can stimulate the sympathetic nervous system, increasing heart rate and blood pressure, which is dangerous for a hypertensive patient. Decongestants are vasoconstrictors; while they are designed for the nasal mucosa, systemic absorption can exacerbate cardiovascular issues.

Bronchodilators: Beta-$2$ Agonists and Methylxanthines

Bronchodilators like beta-$2$ agonists (e.g., albuterol) work by stimulating beta-$2$ receptors on airway smooth muscle to induce relaxation. While these drugs are designed to be selective for the lungs, higher doses can lead to "overflow" where they stimulate beta-$1$ receptors in the heart, causing increased heart rate, palpitations, and elevated blood pressure. CNS effects like nervousness and irritability may also occur. Chronic overuse of rescue inhalers can actually irritate the airway and increase bronchoconstriction, leading to a loss of drug efficacy. Patients experiencing a lack of benefit should be examined for other conditions such as vocal cord dystonia, which mimics asthma but is actually a vocal cord spasm.

Xanthines, specifically methylxanthines like theophylline, are chemically similar to caffeine and act as bronchodilators. Theophylline has a narrow therapeutic range and can accumulate to toxic levels, specifically in patients over the age of $55$, those with infections like pneumonia, or those taking medications that impair liver metabolism, such as cimetidine (an antacid) or ciprofloxacin (an antibacterial). Another option for bronchodilation is the use of anticholinergics, which block the effects of acetylcholine on the airway to maintain patency.

Inhaled Corticosteroids and Airway Inflammation

Controlling airway inflammation is vital for conditions like asthma and COPD, where low-grade inflammation often leads to bronchoconstriction. Inhaled corticosteroids (ICS), such as beclomethasone, are a major advancement because they allow for local delivery to the airway while minimizing systemic side effects such as osteoporosis or metabolic issues. Steroids are lipid-soluble (derived from cholesterol), so they are modified to be soluble in aerosol solutions. In adults, doses of beclomethasone should typically not exceed $300 \text{ micrograms}$ twice a day, with lower doses for children. Combination therapies that join an anti-inflammatory steroid, a beta-$2$ agonist, and an anticholinergic are often highly effective.

For patients concerned about the risks of steroids, such as post-menopausal women worried about bone mineral density loss, research suggests a possible risk of decreased bone density even with inhaled forms. These patients should consult their physicians about maintaining bone health. An alternative group of drugs, cromones (e.g., cromolyn sodium or NasalCrom), prevent the release of histamine by stabilizing respiratory mast cells. However, they must be administered before an allergen challenge to be effective as they do not stop histamine once it is already released.

Supplemental Oxygen, Surfactant, and Nitric Oxide

Supplemental oxygen is critical for increasing tissue oxygenation in patients with chronic pulmonary disease. It can be delivered via compressed air tanks, liquid oxygen reservoirs, or bedside ports. Target oxygen saturation ($S_aO_2$) levels for COPD patients are typically between $88 \text{ to } 92 \%$, whereas other patients target $94 \text{ to } 98 \%$. While oxygen improves exercise tolerance and quality of life, it is potentially toxic. Oxygen metabolism generates reactive oxygen species (ROS), also known as free radicals, which have unpaired electrons in their outer shells. These radicals steal electrons from proteins, DNA, and lipids, causing tissue damage. Signs of oxygen toxicity include muscle twitching, dizziness, confusion, nausea, and convulsions.

Surfactant is a substance that reduces surface tension in the alveoli, allowing them to inflate. It is often administered to premature infants via endotracheal tubes to prevent the alveoli from sticking together, which is a major factor in neonatal survival. Sources of surfactant can be human, animal, or synthetic. Nitric oxide is another neonatal treatment; acting as a vasodilator, it relaxes vascular smooth muscle and is inhaled to facilitate lung perfusion. This improves the ventilation-perfusion ratio ($V/Q$ ratio) and helps prevent chronic lung disease later in life.

Smoking Cessation and Psychotropic Medications

Stopping smoking provides extensive health benefits. Pharmacological aids include nicotine replacement (patches, gum, and e-cigarettes) and drugs like bupropion (marketed as Zyban for smoking cessation or Wellbutrin for depression). These should be part of a comprehensive program including counseling and support groups, as nicotine withdrawal is a powerful syndrome.

Psychotropic medications include sedative-hypnotics and antianxiety drugs. The goal of sedative-hypnotics is to promote sleep that mimics normal EEG patterns. Benzodiazepines (e.g., Valium) are the primary class used for both sleep and anxiety. They bind to a specific benzodiazepine-chloride-GABA channel. When the drug binds, it increases the conductance of negatively charged chloride ions into the neuron, leading to inhibition. Alternatives for sleep include melatonin agonists. For anxiety, buspirone (BuSpar) is a non-GABA-acting drug that stimulates serotonin receptors. It has a slower onset and moderate efficacy compared to benzodiazepines but causes less sedation and has a lower risk of dependence, making it suitable for older patients.

Antidepressants and the BDNF Theory

Depression is a common mental illness characterized by incapacitated sadness. Modern understanding links depression to neurochemical changes in the brain. Antidepressants categorized by the neurotransmitters they affect include selective serotonin reuptake inhibitors (SSRIs like Prozac and Zoloft), selective norepinephrine reuptake inhibitors (SNRIs), tricyclics, and monoamine oxidase (MAO) inhibitors. Most antidepressants work by prolonging the effect of neurotransmitters by inhibiting their reuptake into the presynaptic terminal—where $60 \text{ to } 80 \%$ is normally recycled—or by inhibiting the MAO enzyme which destroys the remaining neurotransmitter.

A prominent theory suggests that increasing these neurotransmitters also increases Brain-Derived Neurotrophic Factor (BDNF). BDNF is a chemical that promotes neurogenesis and the formation of synaptic connections in the hippocampus, a brain region critical for mood control. While reuptake inhibition happens quickly, clinical improvement often takes $1 \text{ to } 2 \text{ weeks}$ to begin and up to $6 \text{ to } 8 \text{ weeks}$ for maximum effect. This time lag is critical, as some patients, especially younger ones, may experience worsening depression or suicidal tendencies during the initial phase. Ketamine has emerged as a rapid-acting alternative for treatment-resistant depression, sometimes showing benefits within an hour, though its abuse potential is high.

Bipolar Disorder, Psychosis, and Alzheimer's

Bipolar disorder is treated with lithium, a mood stabilizer that prevents manic episodes. Lithium is a small ion that is not metabolized and must be eliminated entirely by the kidneys. It has a narrow therapeutic window; toxicity occurs above $2 \text{ milliequivalents}$ and manifests as fine tremors, fatigue, dizziness, and eventual hallucinations or nystagmus (staggering eyes).

Psychosis is characterized by increased dopamine activity in the limbic system. Antipsychotic drugs block dopamine receptors, specifically the $D_2$ subtype. Traditional antipsychotics (e.g., Haldol) are potent blockers, while newer atypical antipsychotics (e.g., Clozaril, Seroquel) are weaker dopamine blockers but also affect serotonin receptors, potentially resulting in fewer side effects. For Alzheimer's disease, medications like memantine (an NMDA receptor blocker) aim to prevent over-excitation of neurons by glutamate.

Seizure Management and Drug Withdrawal

Anti-seizure medications work by increasing inhibition (GABA) or decreasing excitation (modulating sodium or calcium ion channels) in the brain. A significant concern is the risk of birth defects, such as neural tube defects (spina bifida), for women taking these drugs. Patients should never abruptly discontinue medication but should consult a physician to manage risks. For some patients, meds can be successfully withdrawn if they have been seizure-free for at least $2 \text{ years}$, achieved control quickly after initial diagnosis, and had a normal neurological exam prior to withdrawal. About $60 \text{ to } 70 \%$ of patients remain seizure-free after medication withdrawal.